TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia

期刊论文
发表日期：

2024年1月25日

查看全文

Hideaki Ueki,
Chitose Ogawa,
Hiroaki Goto,
Masanori Nishi,
Junko Yamanaka,
Shinji Mochizuki,
Takuro Nishikawa,
Tadashi Kumamoto,
Ritsuo Nishiuchi,
Atsushi Kikuta,
Shohei Yamamoto,
Shunji Igarashi,
Atsushi Sato,
Toshinori Hori,
Akiko M. Saito,
Tomoyuki Watanabe,
Takao Deguchi,
Atsushi Manabe,
Keizo Horibe,
Hidemi Toyoda

摘要

Background

In children with intermediate-risk relapsed acute lymphoblastic leukemia (ALL), allogeneic hematopoietic stem cell transplantation (allo-HSCT) has markedly improved the outcome of patients with an unsatisfactory minimal residual disease (MRD) response. Total body irradiation (TBI), etoposide (ETP), and cyclophosphamide (CY) have been shown to be equivalent to or better than TBI + ETP for conditioning, so we hypothesized that even greater survival could be achieved due to recent advances in HSCT and supportive care.

Procedure

We prospectively analyzed the efficacy and safety of allo-HSCT with a unified conditioning regimen of TBI + ETP + CY in children with intermediate-risk relapsed ALL, based on MRD in the bone marrow after induction, from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) ALL-R08-II nationwide cohort (UMIN000002025).

Results

Twenty patients with post-induction MRD ≥ 10⁻³ and two not evaluated for MRD underwent allo-HSCT. Engraftment was confirmed in all patients, and no transplantation-related mortality was observed. The 3-year event-free survival and overall survival rates after transplantation were 86.4% ± 7.3% and 95.5% ± 4.4%, respectively.

Conclusion

Allo-HSCT based on post-induction MRD with TBI + ETP + CY conditioning was feasible in Japanese children with intermediate-risk relapsed ALL.